Attributes | Values |
---|
rdf:type
| |
Description
| - Favrille Inc is developing FavId, a patient-specific immunotherapy combining tumour-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. Evaluation of this FavId drug has shown that a patient-specific idiotypic vaccine represents a therapeutic agent with clinical potential not only against non-Hodgkin's lymphoma but against other forms of B-cell malignancies, for example, chronic lymphocytic leukemia, mantle cell lymphoma or diffuse large-cell lymphoma.
- Favrille Inc is developing FavId, a patient-specific immunotherapy combining tumour-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. Evaluation of this FavId drug has shown that a patient-specific idiotypic vaccine represents a therapeutic agent with clinical potential not only against non-Hodgkin's lymphoma but against other forms of B-cell malignancies, for example, chronic lymphocytic leukemia, mantle cell lymphoma or diffuse large-cell lymphoma. (en)
- Firma Favrille vyvinula individálně specifickou vakcinu FavId pro léčení lidských nehodgkinských lymfomů . Hodncení této vakcíny ukázalo, že ji lze použít nejen pro léčení těchto lymfomů, ale i pro léčení dalších lymfomů B buněk. (cs)
|
Title
| - Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
- Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma. (en)
- Hodnocení FavId, individuálně specifické vakcíny pro léčení lidských nehodgkinských lymfomů (cs)
|
skos:prefLabel
| - Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
- Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma. (en)
- Hodnocení FavId, individuálně specifické vakcíny pro léčení lidských nehodgkinských lymfomů (cs)
|
skos:notation
| - RIV/68378050:_____/07:00091826!RIV08-AV0-68378050
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/07:00091826
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - non-Hodgkin's lymphoma; lymphoma vaccine FavId (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Current Opinion in Molecular Therapeutics
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |